Alberto Goizueta, MD
Pulmonary Disease · Tampa, FLNPI 1760864045
Payments from drug & device makers
Across 79 payments — averaging $128.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$5K
- Cook Incorporated$2K
- Pulmonx Corporation$545
- Medtronic$502
- ERBE USA Inc$300
- Boehringer Ingelheim$218
- plus $1K from 11 others
What the payments were for
- Speaking & faculty fees$2,04820%
- Travel & lodging$1,97820%
- Food & beverage$4,79547%
- Education$1,30713%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 44 | $5,092 |
| Cook Incorporated | 1 | $2,048 |
| Pulmonx Corporation | 9 | $545 |
| Medtronic | 8 | $502 |
| ERBE USA Inc | 1 | $300 |
| Boehringer Ingelheim | 2 | $218 |
| Cook Medical LLC | 1 | $212 |
| Penumbra, Inc. | 1 | $174 |
| Innovation Technologies Inc | 1 | $174 |
| Galvanize Therapeutics, Inc | 2 | $172 |
| Coaptech, Inc. | 1 | $164 |
| La Jolla Pharmaceutical Company | 1 | $152 |
| United Therapeutics Corporation | 2 | $125 |
| AstraZeneca | 1 | $112 |
| Olympus America Inc. | 2 | $65 |
| Insmed, Inc. | 1 | $57 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,830
- ZEPHYR ENDOBRONCHIAL VALVE$474
- PULMONX CHARTIS TABLET CONSOLE$474
- CHARTIS CATHETER$474
- ZEPHYR DELIVERY CATHETER$474
- CRYO$300
- Blue Rhino$212
- Indigo System$174
- Irrisept$174
- PUMA SYSTEM$164
- ALIYA SYSTEM$137
- ILLUMISITE$131
- superDimension$118
- OFEV$115
- REMODULIN$100
- TYVASO$100
- NONE$100
- DA VINCI SP$100
How this compares
$10,136 in reported general payments places this provider in the 65th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $26,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $455 |
| Fluticasone Propionate | 18 | $290 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Tampa
- Ricardo Restrepo-JaramilloTampa$2.9M
- Rafael MartinezTampa$917K
- Karel CaleroTampa$542K
- Mark RumbakTampa$528K
- Domenick ReinaTampa$469K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.